Novo Nordisk Stock Surges 6% As Wegovy Pill Sales Crush Estimates
Photo: Coinpedia
Novo Nordisk shares climbed more than 6% in early trading on Wednesday after its Wegovy pill outsold expectations and the company raised its full-year guidance. The Danish drugmaker now expects adjusted revenue and operating profit to range from a 2% decline to 2% growth at constant exchange rates, up from a previous forecast of minus 6% to flat. Third-quarter sales rose 4% to 79.2 billion Danish kroner, or $11.9 billion, ahead of the 73.6 billion kroner estimate. The Wegovy pill, launched this year, brought in 5.4 billion kroner against expectations of about 4.5 billion.
Source: Coinpedia
